Last reviewed · How we verify
PHENAZOPYRIDINE
At a glance
| Generic name | PHENAZOPYRIDINE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
Common side effects
- Headache
- rash
- pruritus
- gastrointestinal disturbance
- anaphylactoid-like reaction
- methemoglobinemia
- hemolytic anemia
- renal toxicity
- hepatic toxicity
Key clinical trials
- Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure (NA)
- Prophylactic Analgesia for Bladder Botox Injections (PHASE4)
- Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis (EARLY_PHASE1)
- Effectiveness of Phenazopyridine for Pain Following Urodynamics (PHASE4)
- Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease (PHASE2)
- Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency (NA)
- Identifying Stress Urinary Incontinence in Women With Pelvic Organ Prolapse (NA)
- Using Phenazopyridine for In-office Cystoscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHENAZOPYRIDINE CI brief — competitive landscape report
- PHENAZOPYRIDINE updates RSS · CI watch RSS